Prevalence and correlates of cannabis use for medicinal reasons - An Australian cross-sectional study.
Australia
Cannabis
Cross-sectional studies
Medical cannabis
Medical marijuana
Journal
Addictive behaviors reports
ISSN: 2352-8532
Titre abrégé: Addict Behav Rep
Pays: Netherlands
ID NLM: 101656077
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
17
02
2022
revised:
14
05
2022
accepted:
21
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
It is important to know the prevalence and source of medicinal cannabis use in the population because non-prescribed medicinal use of cannabis products places individuals at higher risk of harms. We estimated the prevalence and correlates of the use of cannabis for medicinal purposes in Australia, three years after Australians were given legal access. Cross-sectional. The 2019 Australian National Drug Strategy Household Survey. Participants were 22,015 Australians aged 14 or above. Self-reported cannabis use in the last 12 months for medicinal purposes only, both medicinal/recreational reasons, or recreationally only. Those who reported medicinal use were asked if it had been prescribed by a doctor. Prevalence estimates were weighted to the population and multinomial logistic regression examined the correlates. The prevalence of any medicinal cannabis use in the past year was 2.6%. Only 0.8% of the sample reported using cannabis solely for medicinal reasons, 95.9% of whom did not have a prescription. A self-reported diagnosis of cancer was associated with medicinal use only. Self-reported chronic pain was associated with both medicinal only and medicinal/recreational use. Medicinal cannabis use was associated with opioids use. In 2019, the prevalence of cannabis use solely for medicinal reasons remains under 1%, was more common among people with specific medical conditions, but most individuals do not have a prescription. The prevalence of self-reported medicinal cannabis use in Australia is low and there is limited use of the legal pathway for medicinal cannabis.
Identifiants
pubmed: 35662918
doi: 10.1016/j.abrep.2022.100436
pii: S2352-8532(22)00031-1
pmc: PMC9160481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100436Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Med J Aust. 2018 Aug 3;209(5):211-216
pubmed: 30092752
Lancet. 2019 Oct 26;394(10208):1580-1590
pubmed: 31657733
Front Psychiatry. 2021 Feb 25;12:551661
pubmed: 33716801
Harm Reduct J. 2020 Jun 8;17(1):37
pubmed: 32513180
Int J Drug Policy. 2020 Dec;86:102971
pubmed: 33038599
Addiction. 2021 May;116(5):1113-1121
pubmed: 33029914
Psychopharmacology (Berl). 2022 May;239(5):1509-1519
pubmed: 35020045
Int J Drug Policy. 2022 Feb;100:103531
pubmed: 34818602
Addict Behav. 2017 Sep;72:14-20
pubmed: 28340421
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12624-12626
pubmed: 31182592
Aust Prescr. 2020 Oct;43(5):152-159
pubmed: 33093741